Sustainability at BD
Working together, we prioritize the health of our -companies, our communities, the planet and the people we serve
- Science Drives Sustainability
- Sustainability at BD Pharmaceutical Systems
- Product Lifecycle Assessment
BD: Science-based Climate Change Initiatives and Targets
The Science-Based
Targets initiative (SBTi)
The Science-Based Targets initiative (SBTi), defines and promotes best practice in
emission reduction and net-zero targets.1 In September 2021, BD strengthened
our commitment to reduce our emissions, by joining the United Nations Race to
Zero via Business Ambition for 1.5°C, and the SBTi.2
"The business benefits of science-based climate action are clear. Leading
companies are already proving that a 1.5°C-compliant business model is possible,
and there is evidence that these companies will be best-placed to thrive as the
global economy undergoes a just transition to a net-zero future by 2050.”
Source Global Compact website
In pursuit of this commitment, BD developed our climate
change targets within 3 scopes.
Scopes 1 and 2
Scopes 1 and 2 address the greenhouse gas (GHG) emissions which arise from our site energy consumption, both directly and indirectly.
Scope 3
Scope 3 addresses our shared emissions, which result from our activity (such as production of raw materials, transport of goods and people) and from assets controlled by stakeholders (such as emissions from suppliers, transporters and subcontractors). Shared emissions arise from all life cycle steps:
- Raw material extraction and delivery
- Downstream pharma customers, patient usage and end-of-life
- BD activities upstream to our pharma customers
Advancing Towards a Healthy Planet, Together
BD ESG: our sustainability plan in more detail
To advance our sustainability credentials, BD developed a comprehensive Environmental and
Social Governance (ESG) strategy.
This strategy identifies five areas, each associated with attainable goals which have the
most potential for generating meaningful and measurable change3:
Climate change
Minimize our contribution to global emissions and help address the unmet health needs of climate-vulnerable populations.
Product impact
Reduce the environmental footprint of our product portfolio and address customer sustainability requirements.
Responsible supply chain
Ensure supply is adaptable to disruption and contributes to strong environmental and social performance.
Human health
Maintain a healthy workforce and a culture of community health.
Transparency
Foster the trust of our stakeholders through transparent reporting on ESG issues relevant to our business.
United Nations Sustainable
Development
BD ESG: our sustainability plan in more detail
The United Nations Sustainable Development Goals (SDGs) also inform our 2030+ ESG goals.4
With our infectious disease diagnosis and management technologies, as well as our work on health worker safety and health system capacity, BD aligns most strongly with UN SDG 3, Good Health and Wellbeing.
We also align with other SDGs that promote universal health including:
-
SDG 5 Gender Equality
-
SDG 8 Decent Work and Economic Growth
-
SDG 9 Industry, Innovation and Infrastructure
-
SDG 13 Climate Action
Sustainability Initiatives in Action
Pioneering the future of healthcare across the globe
BD sustainability initiatives are designed to impact health globally: in our company andcommunities, for the benefit of the planet and for all human health.
The recent BD 2022 ESG report shows that our sustainability initiatives are already working.3
Climate change
Responsible supply chain
Communities
Transparency
To ensure our continued success towards our Sustainability goals, we recognize the
importance of collaboration.
We are proud to include the following among our partners:
Healthcare Plastics Recycling Council (HPRC)
Pharmaceutical Supply Chain Initiative (PSCI)
Healthcare Industry Resilience Collaborative (HIRC)
Race to Zero
International Countil of Nurses
Sustainable Healthcare Coalition
Casella Waste Management
Autoplay:
OFF
Healthcare Plastics Recycling Council (HPRC)
Pharmaceutical Supply Chain Initiative (PSCI)
Healthcare Industry Resilience Collaborative (HIRC)
Race to Zero
International Countil of Nurses
Sustainable Healthcare Coalition
Casella Waste Management
Transparency is also critical to our ESG strategy
Our commitment to good corporate governance is embodied in our Statement of Corporate Governance Principles, while the BD Board of Directors conducts oversight of our ESG goals.
In service of transparency, we submit sustainability data to various organizations and are ranked accordingly:
FTSE4Good
CDP Climate Change B, Water Security B
Ecovadis Bronze 59/100
Green Power Partnership National Top 100 # 98
Green Power Partnership Fortune 500® Partners List #49
Autoplay:
OFF
FTSE4Good
CDP Climate Change B, Water Security B
Ecovadis Bronze 59/100
Green Power Partnership National Top 100 # 98
Green Power Partnership Fortune 500® Partners List #49
BD Medical - Pharmaceutical Systems is Committed to Safety and Sustainability
Sustainability case study with the BD Hypak™ Glass Prefillable Syringe
To align with the BD ESG strategy and to generate meaningful change, BD Medical - Pharmaceutical Systems looked to science to inform our strategy.
The Product Life Cycle Assessment (LCA) is a science-based methodology which determines the environmental impact of all stages within the life cycle of a product. The LCA helps us identify CO2eq hotspots*, prioritize areas for action and make the right decisions for meaningful improvement. Conversely, the LCA prevents us from working on the wrong solutions or from creating impact shifts. This means that we are less likely to unknowingly degrade other stages of the product lifecycle.
Grounded on decades of BD Hypak™ experience, BD Hypak™ for Biotech has been developed to address the key compatibility challenges for biotech drugs and chronic treatments.7
For our first LCA, we selected the entire BD Hypak™ Glass Prefillable Syringe, including the syringe barrel, stopper, plunger rod, needle and cap. We evaluated its complete lifecycle: from the suppliers of our raw material through to manufacturing, patient injection and end-of- life disposal.
The LCA identified priority areas and what we could do in-house, with our suppliers and customers. Based on these results, our team developed a road map towards real-world sustainability improvements:
- Regionalize suppliers to limit air freight
- Replicate manufacturing globally so that pharma companies can regionalize their own supply chains
- Increase the use of renewable energy, reduce energy consumption and waste by BD and BD suppliers
- Introduce recycled content, and integrate eco-design into new product development and continuous improvement
*CO2eq: carbon dioxide equivalent
Safety and sustainability
The LCA methodology is applicable across all our prefillable syringes, safety systems and auto-injector devices. Establishing sustainability goals presents new opportunities for us to further innovate for efficiency and safety, all while reducing the environmental footprint of our products.
Looking ahead
To ensure the longevity of our sustainability goals, the BD Medical - Pharmaceutical Systems Road Map must align with our customers’ and suppliers’ goals.
As we work on Scopes 1 and 2*, we will continue to engage with our industry partners to develop Scope 3, which focuses on shared emissions.**
In order to reach our sustainability targets, collaboration across the industry is essential. Our partnerships are key.
We all benefit from sustainability initiatives: in a spirit of collaboration and mutual support, we will continue Advancing Towards a Healthy Planet, Together.
*Scopes 1 and 2 address the greenhouse gas (GHG) emissions which arise from the energy our sites consume, both directly and indirectly.
**Scope 3 addresses our shared emissions, which result from our activity (such as production of raw materials, transport of goods and people) and from assets controlled by stakeholders (such as emissions from suppliers, transporters and subcontractors).
Explore our products
Prefillable syringe systems
BD is uniquely positioned to offer prefillable syringe systems with expertise in drug container interactions, primary container selection and container/device integration for various drug therapies.
Safety and shielding systems
BD offers a wide range of safety and shielding systems that feature innovative needle shielding system technology for your injectable drug.
Self injection systems
BD partners with you to develop self injection systems that enable drug administration across a range of volumes and viscosities, leveraging BD primary container technologies and expertise with a focus on reaching the market faster.
Plunger Stoppers
With our two stopper processing sites, we aim to offer security of supply and business continuity for your drug combination product needs.
Backstops and plunger rods
As part of our integrated approach to help you develop drug combination products, we offer BD Backstops and BD Plunger Rods in a range of sizes, materials and colors.
Autoplay:
OFF
Prefillable syringe systems
Safety and shielding systems
Self injection systems
Plunger Stoppers
Backstops and plunger rods
- https: //unglobalcompact.org/take-action/events/climate-action-summit-2019/business-ambition
- p. 17 BD FY 2022 Environmental, Social and Governance Report
- p. 13 BD FY 2022 Environmental. Social and Governance Report
- https://sdgs.un.org/goals
- p. 3 BD FY 2022 Environmental. Social and Governance Report
- p. 4 BD FY 2022 Environmental. Social and Governance Report
- Validation Summary Low Tungsten BD HypakTM for Biotech Prefillable Syringe Barrels [Internal Study] Pont-de-Claix, FR: Becton, Dickinson and Company; 2012.